Although THC is popular, marijuana itself has more than 60 cannabinoids, each with its own known set of healing effects. High CBD and low THC products have very minimal psychoactive effects. In cannabis, other than THC, CBD is the most common cannabinoid and is well known to treat, help and prevent seizures, nausea, anxiety, depression, inflammation, psychosis, and is believed to prevent cancer. With over 33 states now having medical cannabis programs, the reality of CBD healing powers are finally surfacing.
Many practitioners continue to prescribe CBD while waiting for the world to fully legalize CBD treatments for pain and other solutions. Winterlife has responded to this need with an inventive assortment of high CBD products with their launching of WinterlifeCBD.
WL is embarking on a vast, multi-state USA expansion by branding a new set of WinterlifeCBD products and a Canadian introduction, once CBD is acceptable in edibles in the country. Additionally, with the advisory services of Redfund’s First Euro Cannabis, the European subsidiary launch for its clients’ CBD products, will be organized with a jump-off in Switzerland where CBD products have been implemented and are currently being sold in most retail stores including international airports.
“The Winterlife brand exuberates a crisp and clean natural feeling. Organic and vegan to appeal to the free spirit of many patients including millennials looking to find a solution to their stress and anxiety conditions. With a goal of helping Winterlife become a public company in the second quarter of 2019, this superior brand will be easily identifiable as any other national or globally recognized cookies and snacks company,” stated Meris Kott, CEO, Redfund Capital Corp.
Redfund Capital announced that it completed its first financing with Winterlife Inc. on November 5, 2018. Redfund and WL signed a 2 year term convertible secured promissory note on November 1, 2018 for CDN $1,000,000 at an annual interest rate of 14% .
About Redfund Capital
Redfund intends to provide debt and equity funding in the mid-to-late stages of a target company’s development, or in technologies that are developed and validated by revenues. The present focus of the merchant bank is on medical cannabis, hemp and CBD-related, healthcare-related target companies.
For further information please visit www.redfundcapital.com
For more information on Redfund Capital contact Meris Kott CEO 604.484.8989 or email@example.com
Further information about the Company is available on www.SEDAR.com under the Company’s profile.
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. Certain statements contained in this release may constitute “forward–looking statements” or “forward-looking information” (collectively “forward-looking information”) as those terms are used in the Private Securities Litigation Reform Act of 1995 and similar Canadian laws. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated”, “anticipates” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the business of the Company, the Property, financing and certain corporate changes. The forward-looking information contained in this release is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.
American cannabis sales hit US$17.5 billion in 2020, a research group’s new study shows.
Meanwhile, a Canadian cannabis producer began offering CBD beverages in the US, another move that shows how interested Canadians are in the overall US cannabis market at the moment.
Some pretty important news out of health and wellness; beverage and natural products company BevCanna Enterprises Inc. (CSE:BEV, Q:BVNNF, FSE:7BC) this week. For those of you following the Company with us, stay tuned.
As investors continue to prioritize cannabis opportunities in the US, market watchers expect mergers and acquisitions (M&A) to play a role in the future for Canadian companies.
A consolidation trend has been expected in the Canadian cannabis space for some time now based on the size of the market compared to the number of operations in the country.
BioHarvest Sciences Inc. Unveils the Unique Polyphenolic Content of Its Upcoming Olive-Based Nutraceutical
The product will include polyphenols known to have significant health benefits.
BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”) has reached an important milestone in its development program of additional Nutraceuticals. The olive-based Nutraceutical product scheduled for market availability in the second half of 2022 will contain the following unique matrix of polyphenols: hydroxytyrosol, trosol, and verbascoside. These compounds are the major polyphenols in naturally grown olives and are responsible for the high antioxidant activity of olives and olive oil. Importantly, the BioHarvest olive-based Nutraceutical product will provide all the benefits of olives and olive oil with a low calorie count per serving.
Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today that it will report financial results for the fourth quarter and full year ended December 31 st , 2020 on Thursday March 25 th , 2021 before the market opens.
The Company will host a conference call and webcast to discuss its financial results and provide investors with key business highlights on Thursday March 25 th , 2021 at 8:30am Eastern Time (7:30am Central Time).